PROCEPT BioRobotics Co. (NASDAQ:PRCT) is Evolutionary Tree Capital Management LLC’s 5th Largest Position

Evolutionary Tree Capital Management LLC lessened its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 12.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 61,118 shares of the company’s stock after selling 8,725 shares during the period. PROCEPT BioRobotics comprises approximately 5.0% of Evolutionary Tree Capital Management LLC’s holdings, making the stock its 5th biggest holding. Evolutionary Tree Capital Management LLC’s holdings in PROCEPT BioRobotics were worth $4,921,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of PRCT. Signaturefd LLC lifted its holdings in PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company’s stock worth $55,000 after buying an additional 145 shares in the last quarter. Naviter Wealth LLC boosted its holdings in PROCEPT BioRobotics by 6.0% in the fourth quarter. Naviter Wealth LLC now owns 3,089 shares of the company’s stock valued at $249,000 after purchasing an additional 176 shares during the last quarter. Amundi grew its stake in PROCEPT BioRobotics by 0.9% during the 4th quarter. Amundi now owns 20,143 shares of the company’s stock valued at $1,742,000 after purchasing an additional 183 shares in the last quarter. Arizona State Retirement System increased its holdings in PROCEPT BioRobotics by 1.5% during the 4th quarter. Arizona State Retirement System now owns 14,285 shares of the company’s stock worth $1,150,000 after purchasing an additional 218 shares during the last quarter. Finally, KRS Capital Management LLC raised its position in shares of PROCEPT BioRobotics by 0.5% in the 4th quarter. KRS Capital Management LLC now owns 46,455 shares of the company’s stock valued at $3,741,000 after purchasing an additional 225 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Trading Up 2.6 %

NASDAQ PRCT opened at $52.07 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. PROCEPT BioRobotics Co. has a one year low of $47.04 and a one year high of $103.81. The company has a 50-day simple moving average of $61.23 and a 200-day simple moving average of $75.72. The firm has a market capitalization of $2.85 billion, a PE ratio of -26.70 and a beta of 1.09.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The company had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. On average, equities analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

Analysts Set New Price Targets

PRCT has been the subject of a number of recent analyst reports. Truist Financial decreased their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a “buy” rating for the company in a research report on Friday. Morgan Stanley cut their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, PROCEPT BioRobotics presently has an average rating of “Moderate Buy” and an average price target of $91.43.

Insiders Place Their Bets

In related news, CFO Kevin Waters sold 733 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares of the company’s stock, valued at $6,161,966.46. This represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Reza Zadno sold 5,475 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the transaction, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,455 shares of company stock valued at $368,322 over the last three months. Company insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).